NO20054794L - 7 ([1, 4] dioksan-2-yl)-benzotiazolderivater som adenosinreseptorligander - Google Patents

7 ([1, 4] dioksan-2-yl)-benzotiazolderivater som adenosinreseptorligander

Info

Publication number
NO20054794L
NO20054794L NO20054794A NO20054794A NO20054794L NO 20054794 L NO20054794 L NO 20054794L NO 20054794 A NO20054794 A NO 20054794A NO 20054794 A NO20054794 A NO 20054794A NO 20054794 L NO20054794 L NO 20054794L
Authority
NO
Norway
Prior art keywords
substituted
receptor ligands
adenosine receptor
unsubstituted
mono
Prior art date
Application number
NO20054794A
Other languages
English (en)
Inventor
Roger David Norcross
Alexander Flohr
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20054794L publication Critical patent/NO20054794L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

hvor R1 er en dioksangruppe som beskrevet i krav 1, og R2 er usubstituert eller substituert -(CH2)n-pyridin-2,3 eller 4-yl; eller er usubstituert eller mono- eller di-substituert -(CH2)n-piperidin-1-yl; eller er usubstituert eller mono- eller di-substi-tuert -(CH2)n-fenyl; eller er benzo[1.3]dioksol-5-yl; eller -(CH2)n-morfolinyl; eller -(CH2)n-tetrahydropyran-4-yl; eller -(CH2)n-O-lavere alkyl; eller -(CH2)n-cykloalkyl; eller -(CH2)n-C(O)-NR'R"; eller -(CH2)n-2-okso-pyrrolidin-1-yl; eller -(CH2)nNR'R"; eller -2-oksa-5-aza-icyklo[2.2.1]heptan-5-yl; eller -1-oksa-8-aza-spiro[4.5]decan-8-yl; og R' og R", uavhengig av hverandre, er lavere alkyl, '(CH2)o-O-lavere alkyl, mono- eller di-substituert cykloalkyl; og n er 0,1, 2 eller 3; m er 0 eller 1; og o er 1 eller 2; og farmasøytisk akseptable syreaddisjonssalter derav. Det er funnet at forbindelsene med den generelle formel I er adenosinreseptorligander med god affinitet til A^-reseptoren og en høy selektivitet overfor Ai- og A3-reseptorer.
NO20054794A 2003-04-14 2005-10-18 7 ([1, 4] dioksan-2-yl)-benzotiazolderivater som adenosinreseptorligander NO20054794L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03008038 2003-04-14
PCT/EP2004/003734 WO2004089949A1 (en) 2003-04-14 2004-04-07 7-([1,4]dioxan-2-yl)-benzothiazole derivatives as adenosine receptor ligands

Publications (1)

Publication Number Publication Date
NO20054794L true NO20054794L (no) 2005-10-27

Family

ID=33104055

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054794A NO20054794L (no) 2003-04-14 2005-10-18 7 ([1, 4] dioksan-2-yl)-benzotiazolderivater som adenosinreseptorligander

Country Status (20)

Country Link
US (1) US6872833B2 (no)
EP (1) EP1615919B1 (no)
JP (1) JP4426569B2 (no)
KR (1) KR100700422B1 (no)
CN (1) CN100447140C (no)
AR (1) AR043845A1 (no)
AT (1) ATE370947T1 (no)
AU (1) AU2004228193B2 (no)
BR (1) BRPI0409402A (no)
CA (1) CA2520852C (no)
CL (1) CL2004000761A1 (no)
CO (1) CO5640107A2 (no)
DE (1) DE602004008447T2 (no)
ES (1) ES2291868T3 (no)
MX (1) MXPA05011102A (no)
NO (1) NO20054794L (no)
RU (1) RU2005135154A (no)
TW (1) TW200427685A (no)
WO (1) WO2004089949A1 (no)
ZA (1) ZA200508180B (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005286593A1 (en) * 2004-09-23 2006-03-30 Reddy Us Therapeutics, Inc. Novel pyridine compounds, process for their preparation and compositions containing them
US7756037B2 (en) * 2006-08-14 2010-07-13 Cisco Technology, Inc. Oversubscription of guaranteed bandwidth
DE102011005232A1 (de) 2011-03-08 2012-09-13 AristoCon GmbH & Co. KG Adenosin und seine Derivate zur Verwendung in der Schmerztherapie
CA2903572A1 (en) * 2013-03-15 2014-10-23 Epizyme, Inc. Substituted benzene compounds
US9243001B2 (en) 2013-03-15 2016-01-26 Epizyme, Inc. Substituted benzene compounds
JP7336434B2 (ja) * 2017-08-01 2023-08-31 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング アデノシン受容体アンタゴニストとしてのチアゾロピリジン誘導体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2413086C (en) 2000-06-21 2011-06-28 Alexander Alanine Benzothiazole derivatives
DE60216823T2 (de) * 2001-03-30 2007-10-04 Pfizer Products Inc., Groton Zwischenprodukten für die Herstellung von Pyridazinon Aldose Reductase Inhibitoren.
US6620811B2 (en) 2001-11-19 2003-09-16 Hoffmann-La Roche Inc. Isonicotin- and nicotinamide derivatives of benzothiazoles
US6734179B2 (en) 2001-12-12 2004-05-11 Hoffmann-La Roche Inc. Benzothiazoles

Also Published As

Publication number Publication date
CN1774437A (zh) 2006-05-17
CN100447140C (zh) 2008-12-31
CO5640107A2 (es) 2006-05-31
ES2291868T3 (es) 2008-03-01
AR043845A1 (es) 2005-08-17
CL2004000761A1 (es) 2005-02-04
US20040204584A1 (en) 2004-10-14
JP4426569B2 (ja) 2010-03-03
EP1615919B1 (en) 2007-08-22
BRPI0409402A (pt) 2006-04-25
WO2004089949A1 (en) 2004-10-21
EP1615919A1 (en) 2006-01-18
AU2004228193B2 (en) 2009-07-23
KR100700422B1 (ko) 2007-03-28
ZA200508180B (en) 2007-03-28
JP2006522765A (ja) 2006-10-05
KR20050111795A (ko) 2005-11-28
CA2520852A1 (en) 2004-10-21
RU2005135154A (ru) 2006-06-27
MXPA05011102A (es) 2005-12-12
DE602004008447T2 (de) 2008-05-21
AU2004228193A1 (en) 2004-10-21
US6872833B2 (en) 2005-03-29
CA2520852C (en) 2011-10-11
ATE370947T1 (de) 2007-09-15
DE602004008447D1 (de) 2007-10-04
TW200427685A (en) 2004-12-16

Similar Documents

Publication Publication Date Title
NO20053762L (no) Kondensert furanforbindelse.
NO20054794L (no) 7 ([1, 4] dioksan-2-yl)-benzotiazolderivater som adenosinreseptorligander
NO20073729L (no) Heterocykliske forbindelser som CCR2B-antagonister
NO20060220L (no) Forbindelser med inhiberene aktivitet mot natriumavhengige transportorer
NO20081074L (no) Macrocyclisk inhibitorer av hepatitis C-virus
TR200100439T2 (tr) 1H-İmidazopiridin türevleri
ATE476431T1 (de) Piperidin- und azetidinderivate als glyt1- inhibitoren
CA2234096A1 (en) 1-(1,2-disubstituted piperidinyl)-4-substituted piperazine derivatives
CO5700774A2 (es) Derivados de triazol como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa-1
RS49850B (sr) Derivati 1,4-benzotiazepin-1,1-dioksida supstituisani radikalima šećera, postupak za njihovu proizvodnju, lekovi koji sadrže ova jedinjenja i njihova primena
JP2006521359A5 (no)
NO331165B1 (no) Derivater av dioksan-2-alkylkarbamater, fremgangsmate for fremstilling derav og anvendelse av de samme for fremstilling av medikamenter
TW200613297A (en) Pyrazole derivatives
DE69811329T2 (de) Imidazolidin-4-on Derivate verwendbar als Antikrebsmittel
FI840653A0 (fi) Imidazo-heterocykliska foereningar, foerfarande foer deras framstaellning och dessa innehaollande farmaceutiska blandningar
DE60236719D1 (de) Purinderivate als antagonisten an purinergen rezeptoren
NO20070173L (no) Nye forbindelser
HU9901221A (hu) Helyettesített triciklusos vegyületek és alkalmazásuk gyógyászati készítményekben
NO20082077L (no) Spirosykliske quinazolinderivater som PDE7-inhibitorer
TW333527B (en) Benzimidazoles, pharmaceutical compositions containing these compounds and processes for preparing them
CA2238817A1 (en) 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)-piperidine derivatives
NO20000722L (no) 2-(4-aryl eller heteroaryl-piperazin-1-ylmetyl)-1H- indolderivater
NO20022232L (no) Imidazolforbindelser for anvendelse som inhibitorer for fosfodiesterase VII
EA200101224A1 (ru) Производные пурина, способ их получения и содержащие их фармацевтические композиции
WO2006034266A3 (en) Sulfonyl hydrazines as hypoxia-selective antineoplastic agents

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application